Healthcare Industry Media Coverage2017-09-13T20:18:16+00:00

Media Coverage

Pro-AbbVie Bias May be Driving Rheumatologist Confidence in Newcomer Rinvoq: Analyst

From: FiercePharma By: Kyle Blankenship           Pro-AbbVie Bias May be Driving Rheumatologist Confidence in Newcomer Rinvoq: Analyst Between AbbVie's two newly approved blockbusters-in-waiting, psoriasis med Skyrizi's booming sales have drawn some analysts' eyes away from highly-touted rheumatoid arthritis drug Rinvoq. But among physicians, Rinvoq is becoming a darling, one analyst says––and an "AbbVie halo" could be major part of that...(read more).

December 4, 2019|

Ocrevus Top Choice of US Neurologists for Active SPMS, But Mayzent and Mavenclad Gaining Interest, Report Says

From: Multiple Sclerosis News Today By: Ana Pena, PHD       Ocrevus Top Choice of US Neurologists for Active SPMS, But Mayzent and Mavenclad Gaining Interest, Report Says Genentech‘s Ocrevus (ocrelizumab) continues to be the most prescribed medication to reduce inflammatory disease in people with active secondary progressive multiple sclerosis (SPMS) among U.S. neurologists, even though Novartis’ Mayzent (siponimod) and EMD Serono’s Mavenclad (cladribine) were approved in March to treat this same MS group, according to a 2019 report by Spherix Global Insights...(read more).

November 22, 2019|

Biogen Drops After Piper Jaffray Downgrade, Price Target Cut

From: TheStreet By: Tony Owusu               Biogen shares were falling in trading Friday after analysts at Piper Jaffray downgraded the stock to neutral from overweight on concerns about competitive pressures for the suite of the company's multiple sclerosis treatments. The firm also lowered its price target to $250 from $280 per share. Shares fell in trading by 1.4% to $236.36. Piper Jaffray analyst Christopher Raymond cited new neurologist survey data from Spherix Global Insights that "spells bad news for both Tecfidera and Tysabri in the near and long term." The company's Tecfidera multiple sclerosis [...]

June 28, 2019|

Biogen Stock Is Slipping Because a Multiple Sclerosis Drug Has Fierce Competition

From: Barron's By: Josh Nathan-Kazis               Biogen stock was slipping on Friday morning as one analyst warned that the company’s drug for multiple sclerosis could be losing ground to new competitors. Citing data from a proprietary survey of doctors treating MS patients, PiperJaffray analyst Christopher Raymond outlined threats to the market share of Biogen’s Tysabri from Novartis’ (NVS) newly-approved MS drug Mayzent and Roche’s (CH:ROG) drug Ocrevus...(read more).

June 28, 2019|

DMT Choice for Your MS Is Your Decision

About 15 disease-modifying therapies (DMTs) are available to treat MS these days. So, choosing which to use can be daunting. I’ve been treated with four DMTs since I was first prescribed Avonex (interferon beta-1a) back in 1996. Each time I’ve switched treatments, my neurologist has suggested a number of DMTs she thought would be best for me. But she left the final decision in my hands.

March 19, 2019|